西格列汀对老年2型糖尿病合并轻中度慢性心衰患者hs-CRP及NT-proBNP的影响

Effect of Sitagliptin on Peripheral Serum Levels about hs-CRP, NT-proBNP of elderly Patients who Suffer from Type 2 Diabetes with Mild to Moderate Chronic Heart Failure

目的:探讨使用西格列汀对老年2型糖尿病合并轻中度慢性心衰患者外周血超敏C反应蛋白(high-sensitivity C-reactive Protein,hs-CRP)、N-端B型脑钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-proBNP)的影响。方法:将我院90例老年2型糖尿病合并轻中度慢性心衰患者随机分成观察组和对照组分别46例和44例。两组患者均给予常规抗心衰治疗,对照组予以格列吡嗪控释片降糖,观察组予以西格列汀口服降糖治疗。检测试验前后患者血清hs-CRP及NT-proBNP的水平,并常规检测血压、血脂、糖化血红蛋白、血糖及肝肾功能等指标。结果:两组治疗后HbA1c水平与治疗前比较均有下降,差异均有统计学意义(P<0.05);西格列汀组的hs-CRP、NT-proBNP水平治疗后分别下降至6.67±0.85 mg/L,1412.27±92.28 pg/m L,与治疗前比较差异均有统计学意义(P<0.05);治疗后西格列汀组的hs-CRP、NT-proBNP水平与对照组比较差异有统计学意义(P<0.05)。结论:2型糖尿病合并轻中度慢性心功能不全患者服用西格列汀除有效降糖外还能一定程度地降低hs-CRP和NT-proBNP水平,提示其潜在改善心脏功能的作用。

Objective： This study was designed to investigate the effection of Sitagliptin on peripheral serum levels about high-sensitivity C-reactive Protein（hs-CRP）, N-terminal pro-B-type natriuretic peptide （NT-proBNP） of elderly patients who suffer from type 2 di- abetes with mild to moderate chronic heart failure. Methods： 90 cases of our hospital elderly patients who suffer from type 2 diabetes with mild to moderate chronic heart failure were randomly divided into two groups. The observation group contains 46 cases and the control group is 44 cases, respectively. Two groups were applied with conventional heart failure treatments, the control group received glipizide, while the observation group were given sitagliptin. The serum levels of hs-CRP and NT-proBNP were detected both before and after the test, with routine tests of blood pressure, blood-lipids, glycated hemoglobin, glucose, hepatic and renal function and other indicators. Results： Compared with before treatments, the HbAlc levels of the two groups after treatment were decreased, the differences were statistically significant （P〈0.05）; The serum levels ofhs-CRP and NT-proBNP in sitagliptin group were decreased to 6.67± 0.85mg/L and 1412.27± 92.28 pg/mL after the treatments. The differences were both statistically significant （P〈0.05） by comparing with the serum levels before the treatments. After the treatments, the differences of serum levels of hs-CRP and NT-proBNP in the sitagliptin group was statistically significant compared with control group （P〈0.05）. Conclusion： In type 2 diabetes patients with mild to moderate chronic heart failure patients, taking Sitagliptin can decrease blood glucose effectively,meanwhile reduce the hs-CRP and NT-proBNP levels at some extent, It can reveal that Sitagliptin may have the potential to improve cardiac function.